What do systematic reviews say?

Fluoxetine vs milnacipran

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with milnacipran (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.2 [0.78, 1.84]
  2 studies · 370 participants
  Moderate

Fluoxetine vs mirtazapine

Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with mirtazapine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.46 [1.04, 2.04]
  4 studies · 600 participants
  Moderate

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.27 [0.92, 1.75]
  7 studies · 721 participants
  Moderate

Fluoxetine vs nefazodone

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs paroxetine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with paroxetine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.23 [0.93, 1.65]
  9 studies · 1574 participants
  Moderate

Fluoxetine vs phenelzine

It is very uncertain whether fluoxetine changes failure to respond (reduction ≥ 50% on HDRS) compared with phenelzine (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.42 [0.27, 7.34]
  1 study · 40 participants
  Very low